List of Personalized Medicine Companies in Pennsylvania - 11

BlueSphere Bio was founded to unlock the potential of personalized T cell therapy for the treatment of cancer by harnessing the unique specificity of each patient’s own T cells for the particular molecular fingerprint of each patient’s own cancer through our novel TCXpress technology. Our proprietary TCXpress platform is an elegant, rapid approach that exploits the patient’s own immune defenses to attack their cancer specifically, and is designed to leave normal tissues untouched, thereby reducing harmful side effects. The platform and implementation allows us to deliver rapid, personalized T cell treatments for a variety of cancer indications.

Chimeron Bio is a biotechnology company focused on developing personalized gene therapies, including self-amplifying RNA vaccines and therapeutics designed on its proprietary technology.

Fore Biotherapeutics - We are a precision oncology company pioneering the development of cancer therapies guided by our proprietary functional genomics. Deeply rooted in science and innovation, our vision is to compassionately contribute to solving cancer.

The OcuCheck is a point-of-care device that uses a specialized electrical chemical sensor with proprietary coatings to measure specific biomarkers in the tear film Currently, the OcuCheck is the only device that can simultaneously measure MMP-9 and tear film osmolarity in one device. It is also one of the most accurate devices for quantitative measurement of MMP-9.

JBS Science is a biotechnology company that specializes in developing circulating cell-free DNA (cfDNA) in urine technology for improved cancer screening and management through liquid biopsy.

LabyRx Immuno-Oncology is a bio-medical company focused on developing a comprehensive platform for treating adenocarcinomas, a class of glandular-related tumors that represent approximately 40% of worldwide cancer cases and 50% of treatment-related spending. Based upon our scientists' discovery and ongoing research into the unique adenocarcinoma target – Labyrinthin – the Company aims to advance novel cancer therapeutic technologies that improve treatment processes. The team comprise renown scientists in the United States and Hong Kong working towards cancer therapeutics and diagnostics.

Patient populations and their medications are continuously moving. MedTek21 ensures your entire patient base is continuously monitored for potential drug/gene interaction risks, allowing you to focus your care.

PCI is your world leading CDMO, providing integrated end-to-end drug development, manufacturing, and packaging solutions to increase product speed to market and opportunities for commercial success. PCI brings the proven experience that comes with more than 90 successful product launches each year and over five decades in the delivery of CDMO services. With 30 sites across Australia, Canada, North America, the UK, and Europe and over 6000+ dedicated employees, together, delivering life changing therapies. Leading technology and continued investment enable us to deliver development to commercialization solutions throughout the product lifecycle, collaborating with our clients to improve the lives of patients globally.

Plexision develops cellular biomarkers for personalized diagnosis and drug development in solid organ transplantation, and immunological disorders. Plexision's first patented product, the PleximmuneTM assay, predicts the risk of transplant rejection. The test is based on patent-pending technology to measure antigen-specific white blood cells. Testing services for transplant recipients and drug developers are provided at Plexision's CLIA-certified, central laboratory in Pittsburgh. Plexision currently offers cell-based testing for personalized assessment of rejection risk after solid organ transplantation The Pleximmune blood test is the first such test offered for children with liver or intestine transplantation.

Our mission at Predictive Oncology is to change the landscape of oncology drug discovery and enable the development of more effective therapies in the treatment of cancer. By harnessing the power of machine learning, scientific rigor and biologics, we can improve the probability of success and advance drug compounds with a higher degree of confidence. We invite you to follow us to stay up-to-date about our latest developments.

The Northeast Biomanufacturing Center and Collaborative (NBC2) is a National Science Foundation Advanced Technology Educationregional center that has been in existence since 2005. It's mission is tocoordinate local and regional efforts into a national biomanufacturing education and training system to promote, create, and sustain a qualified workforce with a vision to be the nationally recognized center of excellence that develops a world-class sustainable biomanufacturing workforce to improve the quality of life.